Drugs that contain Afatinib Dimaleate
1. Drug name - GILOTRIF
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE43431 | BOEHRINGER INGELHEIM | Quinazoline derivatives and pharmaceutical compositions containing them |
Jan, 2026
(3 years from now) | |
| US8426586 | BOEHRINGER INGELHEIM | Process for preparing amino crotonyl compounds |
Oct, 2029
(7 years from now) | |
| CN101402631A | BOEHRINGER INGELHEIM | Amino Quinazoline Dimaleate, Method For Production Thereof And Use Thereof |
Dec, 2013
(8 years ago) | |
| CN1481370A | BOEHRINGER INGELHEIM | Quinazoline Derivatives, Pharmaceutical Compositions Containing These Compounds, Their Use And Process For Their Manufacture |
Dec, 2021
(9 months ago) | |
| CN1277822C | BOEHRINGER INGELHEIM | Quinazoline Derivatives, Pharmaceutical Compositions Containing These Compounds, Their Use And Process For Their Manufacture |
Dec, 2021
(9 months ago) | |
| CN1867564A | BOEHRINGER INGELHEIM | Method For Preparing Amino Croton Radical Compound |
Oct, 2024
(2 years from now) | |
| CN1867564B | BOEHRINGER INGELHEIM | Method For Preparing Amino Croton Based Compound |
Oct, 2024
(2 years from now) | |
| IN224186B | BOEHRINGER INGELHEIM | Quinazoline Compounds And Process Thereof |
Dec, 2021
(9 months ago) | |
| IN200300822P1 | BOEHRINGER INGELHEIM | Quinazoline Compounds And Process Thereof |
Dec, 2021
(9 months ago) | |
| EP2508521B1 | BOEHRINGER INGELHEIM | Method For The Production Of Amino Crotonyl Compounds |
Oct, 2024
(2 years from now) | |
| EP2508521A2 | BOEHRINGER INGELHEIM | Dimaleat Of An Amino Crotonyl Compound And Method Of Production Thereof |
Oct, 2024
(2 years from now) | |
| EP1678165B1 | BOEHRINGER INGELHEIM | Method For The Production Of Amino Crotonyl Compounds |
Oct, 2024
(2 years from now) | |
| EP2508521A3 | BOEHRINGER INGELHEIM | Method For The Production Of Amino Crotonyl Compounds |
Oct, 2024
(2 years from now) | |
| EP1678165A2 | BOEHRINGER INGELHEIM | Method For The Production Of Amino Crotonyl Compounds |
Oct, 2024
(2 years from now) | |
| EP1345910B1 | BOEHRINGER INGELHEIM | Quinazoline Derivatives, Medicaments Containing Said Compounds, Their Utilization And Method For The Production Thereof |
Dec, 2026
(4 years from now) | |
| EP1345910A1 | BOEHRINGER INGELHEIM | Quinazoline Derivatives, Medicaments Containing Said Compounds, Their Utilization And Method For The Production Thereof |
Dec, 2026
(4 years from now) | |
| EP1345910B9 | BOEHRINGER INGELHEIM | Quinazoline Derivatives, Medicaments Containing Said Compounds, Their Utilization And Method For The Production Thereof |
Dec, 2026
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE43431
(Pediatric) | BOEHRINGER INGELHEIM | Quinazoline derivatives and pharmaceutical compositions containing them |
Jul, 2026
(3 years from now) | |
| US9539258 | BOEHRINGER INGELHEIM | Quinazoline derivatives for the treatment of cancer diseases |
Nov, 2026
(4 years from now) | |
|
US9539258
(Pediatric) | BOEHRINGER INGELHEIM | Quinazoline derivatives for the treatment of cancer diseases |
May, 2027
(4 years from now) | |
| US8545884 | BOEHRINGER INGELHEIM | Solid pharmaceutical formulations comprising BIBW 2992 |
Dec, 2029
(7 years from now) | |
|
US8426586
(Pediatric) | BOEHRINGER INGELHEIM | Process for preparing amino crotonyl compounds |
Apr, 2030
(7 years from now) | |
|
US8545884
(Pediatric) | BOEHRINGER INGELHEIM | Solid pharmaceutical formulations comprising BIBW 2992 |
Jun, 2030
(7 years from now) | |
| US10004743 | BOEHRINGER INGELHEIM | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
Jul, 2030
(7 years from now) | |
|
US10004743
(Pediatric) | BOEHRINGER INGELHEIM | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
Jan, 2031
(8 years from now) | |
Treatment: Treatment of patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 20MG BASE | TABLET;ORAL | Prescription |
| EQ 30MG BASE | TABLET;ORAL | Prescription |
| EQ 40MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.